ALPN Projected Dividend Yield

Alpine Immune Sciences Inc ( NASDAQ : ALPN )

Alpine Immune Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to autoimmune and inflammatory diseases. Co.'s ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor, and a proliferation inducing ligand, cytokines, which play the roles in the activation, development, and survival of B cells. Co.'s ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator and CD28 antagonist used for the treatment of autoimmune and inflammatory diseases. In immuno-oncology, Co.'s ALPN-202 (davoceticept) is a conditional CD28 costimulator and dual checkpoint inhibitor used for the treatment of cancer.

20 YEAR PERFORMANCE RESULTS